Ranitidine tablets IP refers to ranitidine hydrochloride tablets manufactured in India, adhering to the Indian Pharmacopoeia (IP) standards. Ranitidine is a medication that decreases the amount of acid the stomach produces. It was commonly used to prevent and treat heartburn, indigestion, and stomach ulcers.
What happened to ranitidine?
Ranitidine products were voluntarily recalled and removed from the market in 2020 by manufacturers, including those in India, due to concerns about the presence of a probable human carcinogen called N-nitrosodimethylamine (NDMA) [1][2]. NDMA is a substance that can form in ranitidine over time and with storage conditions [3]. Regulatory agencies like the U.S. Food and Drug Administration (FDA) requested the withdrawal of all prescription and over-the-counter ranitidine products [3].
Why was NDMA found in ranitidine?
NDMA is a common environmental contaminant and is not expected to cause cancer with short-term exposure. However, elevated levels of NDMA were detected in ranitidine products. Investigations suggested that NDMA could form in ranitidine over time, and potentially at higher levels when stored at elevated temperatures [3]. The exact mechanism of NDMA formation in ranitidine has been a subject of study, with some research pointing to the intrinsic instability of the ranitidine molecule itself [4].
What are the alternatives to ranitidine?
Several alternatives are available for conditions previously treated with ranitidine, including other histamine-2 (H2) blockers and proton pump inhibitors (PPIs).
* H2 Blockers: Medications like famotidine (Pepcid) and cimetidine (Tagamet) work similarly to ranitidine by reducing stomach acid production [5].
* Proton Pump Inhibitors (PPIs): Drugs such as omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), and pantoprazole (Protonix) are generally more potent in reducing stomach acid [5].
These alternatives are considered safe and effective for managing heartburn, GERD, and ulcers.
Who manufactured ranitidine tablets IP?
Prior to its market withdrawal, numerous pharmaceutical companies manufactured ranitidine tablets IP in India. These included both large generic drug manufacturers and smaller regional companies. Specific manufacturers varied, and products were distributed under various brand names and as generic equivalents. Information on specific manufacturers before the recall can be found through historical pharmaceutical databases and regulatory filings.
When did ranitidine get recalled?
The voluntary recalls of ranitidine products began in late 2019 and continued into 2020, culminating in requests from regulatory bodies, such as the FDA in April 2020, for manufacturers to remove all ranitidine products from the market [1][3].
What are the risks associated with NDMA?
NDMA is classified as a probable human carcinogen. While the levels detected in ranitidine were often low, the FDA determined that some ranitidine products contained unacceptable levels of NDMA [3]. Long-term exposure to elevated levels of NDMA could potentially increase the risk of cancer [3].
Sources:
[1] https://www.drugpatentwatch.com/blog/ranitidine-recall-a-look-back-at-the-ndma-controversy
[2] https://www.drugpatentwatch.com/blog/ranitidine-recall-a-look-back-at-the-ndma-controversy/
[3] https://www.fda.gov/drugs/drug-safety-and-availability/FDA-nprm-announces-company-requests-voluntary-withdrawal-all-prescription-and-over-counter-ranitidine
[4] https://www.drugpatentwatch.com/blog/ranitidine-recall-a-look-back-at-the-ndma-controversy/
[5] https://www.fda.gov/drugs/drug-safety-and-availability/ranitidine-ndma-and-cancer-risk-frequently-asked-questions